Koch, Elias A. T.
Petzold, Anne
Wessely, Anja
Dippel, Edgar
Eckstein, Markus
Gesierich, Anja
Gutzmer, Ralf
Hassel, Jessica C.
Knorr, Harald
Kreuzberg, Nicole
Leiter, Ulrike
Loquai, Carmen
Meier, Friedegund
Meissner, Markus
Mohr, Peter
Pföhler, Claudia
Rahimi, Farnaz
Schadendorf, Dirk
Schlaak, Max
Thoms, Kai-Martin
Ugurel, Selma
Utikal, Jochen
Weichenthal, Michael
Schuler-Thurner, Beatrice
Berking, Carola
Heppt, Markus V.
Article History
Received: 23 November 2022
Accepted: 6 March 2023
First Online: 4 July 2023
Compliance with ethics guidelines
: This study was approved by the institutional review board of the medical faculty of the Munich University Hospital (approval number 413-16 UE) and was conducted following the principles of the <i>Helsinki Declaration</i> in its current version. The Patient consent was waived due to retrospective design involving anonymized data from several centers.
: <i>Conflict of Interests</i> M.E.: Personal fees, travel costs and speaker’s honoraria from MSD, AstraZeneca, Janssen-Cilag, Cepheid, Roche, Astellas, Diaceutics; research funding from AstraZeneca, Janssen-Cilag, STRATIFYER, Cepheid, Roche, Gilead; advisory roles for Diaceutics, MSD, AstraZeneca, Janssen-Cilag, GenomicHealth; outside the submitted work. A.G.: Speaker’s honoraria from Allmiral, Bristol-Myers Squibb, MSD Sharp & Dohme and Roche; intermittent advisory board relationships with Amgen, Bristol-Myers Squibb, Novartis, MSD Sharp & Dohme, Pierre Fabre Pharmaceuticals, Pfizer, Roche and Sanofi Genzyme; travel and congress fee support from Bristol-Myers Squibb, MSD Sharp & Dohme, Novartis, Pierre Fabre Pharmaceuticals and Roche. Clinical studies with Amgen, Array, Bristol-Myers Squibb, Delcath Systems Inc, GSK, Novartis, Merck, MSD Sharp & Dohme, Pfizer and Roche. R.G.: Research support: Pfizer, Johnson & Johnson, Novartis, SUN, Amgen, Sanofi, Merck-Serono, Kyowa-Kirin, Almirall-Hermal. Honoraria for lectures: Roche Pharma, Bristol-MyersSquibb, Novartis, MSD, Almirall-Hermal, Amgen, Merck-Serono, Bayer, SUN, Pierre-Fabre, Sanofi. Honoraria for advice: Roche Pharma, Bristol-MyersSquibb, Novartis, MSD, Almirall-Hermal, Amgen, Pierre-Fabre, Merck-Serono, 4SC, SUN, Merck-Serono, Sanofi, Immunocore; outside the submitted work. C.L. received Advisory board, Speekers fee, travel reimbusment from MSD, BMS, Sanofi, Pierre Fabre, Roche, Novartis, Biontech, Almirall Hermal, Sun Pharma, Kyowa Kirin, Merck, Immunocore. F.M.: Travel support or/and speaker’s fees or/and advisor’s honoraria by Novartis, Roche, BMS, MSD, Pierre Fabre, Sanofi and Immunocore and research funding from Novartis and Roche; outside the submitted work. K.-M.T.: Honoraria from BMS, MSD, Roche, Novartis, Pierre Fabre, Sun Pharma, LEO, Almirall, Galderma, Candela; Consultant or Advisory Role for BMS, MSD, Roche, Novartis, Pierre Fabre, Sun Pharma, LEO, Almirall; Travel support from BMS, MSD, Roche, Novartis, Pierre Fabre, LEO; outside the submitted work. C.P.: Received honoraria (speaker honoraria or honoraria as a consultant) and travel support from: Novartis, BMS, MSD, Merck Serono, MSD, Celgene, AbbVie, Sunpharma, Pierre Fabre, UCB, Nutricia Milupa, Janssen and LEO outside the submitted work. S.U.: Research support from Bristol Myers Squibb and Merck Serono; speakers and advisory board honoraria from Bristol Myers Squibb, Merck Sharp & Dohme, Merck Serono, and Novartis, and travel support from Bristol Myers Squibb, Merck Sharp & Dohme, and Pierre Fabre; outside the submitted work. J.U.: Advisory board or has received honoraria and travel support from Amgen, Bristol Myers Squibb, GSK, Immunocore, LeoPharma, Merck Sharp and Dohme, Novartis, Pierre Fabre, Roche, Sanofi outside the submitted work. A.W.: Speaker’s honoraria from Novartis; outside the submitted work. All others authors declare no conflicts of interest.